$9.01
4.91% yesterday
Nasdaq, Nov 15, 10:00 pm CET
ISIN
US86889P1093
Symbol
SRZN

Surrozen Inc Stock price

$9.01
-1.69 15.75% 1M
-1.14 11.21% 6M
-0.39 4.10% YTD
+3.31 57.98% 1Y
-133.49 93.67% 3Y
-142.64 94.06% 5Y
-142.64 94.06% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.47 4.91%
ISIN
US86889P1093
Symbol
SRZN
Sector

Key metrics

Market capitalization $29.30m
Enterprise Value $-180.00k
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.01
EV/Sales (TTM) EV/Sales -0.02
P/S ratio (TTM) P/S ratio 2.93
P/B ratio (TTM) P/B ratio 5.17
Revenue growth (TTM) Revenue growth -20.00%
Revenue (TTM) Revenue $10.00m
EBIT (operating result TTM) EBIT $-26.63m
Free Cash Flow (TTM) Free Cash Flow $-28.43m
Cash position $31.01m
EPS (TTM) EPS $-16.99
P/E forward negative
Short interest 1.47%
Show more

Is Surrozen Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Surrozen Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Surrozen Inc forecast:

1x Buy
50%
1x Hold
50%

Analyst Opinions

2 Analysts have issued a Surrozen Inc forecast:

Buy
50%
Hold
50%

Financial data from Surrozen Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
10 10
20% 20%
100%
- Direct Costs 1.57 1.57
45% 45%
16%
8.43 8.43
13% 13%
84%
- Selling and Administrative Expenses 13 13
10% 10%
132%
- Research and Development Expense 20 20
27% 27%
203%
-25 -25
23% 23%
-251%
- Depreciation and Amortization 1.57 1.57
45% 45%
16%
EBIT (Operating Income) EBIT -27 -27
25% 25%
-266%
Net Profit -44 -44
27% 27%
-444%

In millions USD.

Don't miss a Thing! We will send you all news about Surrozen Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Surrozen Inc Stock News

Neutral
GlobeNewsWire
9 days ago
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today announced that Craig Parker, President and Chief Executive Officer, will present at two upcoming healthcare investor conferences.
Neutral
GlobeNewsWire
10 days ago
Substantial enrollment progress in Phase 1b trial of SZN-043 in severe alcohol-associated hepatitis patients with proof-of-concept data expected in the first half of 2025 Nominated novel portfolio of preclinical ophthalmology product candidates to R&D pipeline Received $10 million milestone payment from Boehringer Ingelheim strategic collaboration on SZN-413 in retinal vascular associated disea...
Neutral
GlobeNewsWire
12 days ago
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today announced a strategic research collaboration with privately-held TCGFB, Inc. (“TCGFB”) to discover antibody therapeutics targeting Transforming Gr...
More Surrozen Inc News

Company Profile

Surrozen, Inc. is a preclinical stage biotechnology company, which engages in discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. It is also focused on developing tissue-specific antibodies designed to engage the body's existing biological repair mechanisms with potential application across multiple disease areas, including inflammatory bowel disease, hepatitis, eye diseases, hearing loss, lung and airway diseases, and certain neurological disorders. The company was founded on August 12, 2015 and is headquartered in South San Francisco, CA.

Head office United States
CEO Craig Parker
Employees 42
Founded 2015
Website www.surrozen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today